Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Calquence
Pharma
AstraZeneca trumpets new Calquence combos in CLL
With the AMPLIFY trial win, the combination of Calquence, venetoclax and Gazyva may become the first triplet regimen in CLL.
Angus Liu
Jul 29, 2024 10:25am
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
Lilly's Jaypirca blazes CLL trail with FDA approval
Dec 4, 2023 4:11am
Questions swirl around AstraZeneca's cancer drugs
Nov 9, 2023 11:39am
NICE signs off on AbbVie, J&J's Imbruvica-Venclyxta combo in CLL
Apr 21, 2023 11:30am
